How powerful is ADC, the new innovative modular missile drug, and why is Pfizer willing to spend US$43 billion to snatch the acquisition of Seagen from Merck (MSD)? The strong merger opens up unlimited business opportunities for ADC Antibody Drug Conjugate (ADC), what are the hidden business opportunities and commercial value?

Pfizer once again to acquire, in addition to benefit from the COVID-19 best-selling vaccine (Pfizer/BNT) business outside the epidemic of the financial momentum brought about by the strong, expanding the product portfolio to drive the growth of innovative drug sales is still the international pharmaceutical companies to create revenue unchanged keynote. According to the financial report, Seagen's revenue will reach US$2 billion in 2022, a year-on-year growth of 23% compared to 2021, with the main revenue contributions coming from three aspects: the four existing marketed drugs, royalties, and collaboration licensing agreements, etc., of which the four marketed drugs include three ADC drugs for the treatment of lymphomas (Adcetris), and three ADC drugs for the treatment of lymphomas (Adcetris).^®with sales of $839 million in 2022), bladder cancer (Padcev^®(Tivdak) and cervical cancer (Tivdak), with sales of US$451 million in 2022.^®(with sales of $63 million in 2022), and a small molecule chemical for colorectal cancer treatment (Tukysa^®Pfizer's new ADC drug, Mylotargine, is expected to exceed $10 billion in revenue growth by 2030 as the company expands the benefits of the new indication extensions for these drugs and approvals of other new ADC drug candidates. Historically, Pfizer's new ADC drug, Mylotarg, has been shown to be a significant contributor to the company's growth.^®The acquisition of Seagen's key internal ADC technology will help Pfizer master the ADC core technology platform in depth, and will continue the development of the existing ADC new drug candidates, thus enhancing Pfizer's leading position in the anticancer drug market in the future.